Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals (NQ: AGIO )

31.50 -1.19 (-3.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 605,230
Open 32.84
Bid (Size) 31.15 (1)
Ask (Size) 31.86 (1)
Prev. Close 32.69
Today's Range 31.00 - 33.46
52wk Range 19.80 - 35.50
Shares Outstanding 58,951,469
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Attention Biotech Investors - Stocks To Watch
RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences,... 
Via Benzinga
AGIO Stock Earnings: Agios Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
AGIO stock results show that Agios Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+37.98%
+37.98%
1 Month
-0.54%
-0.54%
3 Month
-4.52%
-4.52%
6 Month
+41.07%
+41.07%
1 Year
+22.05%
+22.05%

More News

Read More
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
Via InvestorPlace
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
Via Investor's Business Daily
Earnings Scheduled For February 15, 2024
Via Benzinga
Earnings Preview: Agios Pharmaceuticals
Via Benzinga
RBC Capital Maintains Outperform Rating for Agios Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Agios Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Agios Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Agios Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
7 Biotech Stocks Fighting America’s Deadliest Diseases
Via InvestorPlace
Why Is Blood Disorder Focused Agios Pharmaceuticals Stock Trading Higher Today?
Via Benzinga
Agios Pharma Surges, And Retakes Its 200-Day Line, On Promising Test Results For Thalassemia Drug
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Agios Touts Encouraging Action From Sickle Cell Disease Study With Mitapivat
Via Benzinga
Why Shares of Schrödinger Rose This Week
Via The Motley Fool
7 Biotech Stocks to Buy for 100% Returns
Via InvestorPlace
7 Biotech Stocks That Could Be the Next Big Thing
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
Via Benzinga
3 Under-the-Radar Biotech Stocks to Buy in 2022
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Via Benzinga
Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients
Via Benzinga
Agios Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.